Trial Profile
A Randomized, Double-blind, Placebo-controlled First-in-human Study to Assess the Safety, Tolerability and Pharmacokinetcs of Single and Multiple Ascending Doses of QCC374 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Mar 2016
Price :
$35
*
At a glance
- Drugs QCC 374 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors Novartis
- 20 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 25 Sep 2014 New trial record